Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice

Metabolism: Clinical and Experimental

Volumn 53, Issue 11, 2004, Pages 1473-1479

  Tanimoto, Mitsuo ^a   Fan, Qiuling ^a   Gohda, Tomohito ^a   Shike, Toshihide ^a   Makita, Yuichiro ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; ENDOTHELIAL CONSTITUTIVE NITRIC OXIDE SYNTHASE; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; PIOGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; GLOMERULUS; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; IMMUNOFLUORESCENCE; KIDNEY CIRCULATION; MALE; MICROALBUMINURIA; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINARY EXCRETION;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG ADMINISTRATION SCHEDULE; FLUORESCENT ANTIBODY TECHNIQUE; HYPOGLYCEMIC AGENTS; KIDNEY GLOMERULUS; MALE; MICE; MICE, INBRED STRAINS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; SERUM ALBUMIN; THIAZOLIDINEDIONES;

EID: 6944250878     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.06.016     Document Type: Article

References (42)

1. Day C. Thiazolidinediones A new class of antidiabetic drugs. Diabet Med. 16:1999;179-192
2. Schwartz S., Raskin P., Fonseca V., et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus Troglitazone and Exogenous Insulin Study Group. N Engl J Med. 338:1998;861-866
3. Imano E., Kanda T., Nakatani Y., et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 21:1998;2135-2139
4. Fujii M., Takemura R., Yamaguchi M., et al. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism. 46:1997;981-983
5. Yang T., Michele D.E., Park J., et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol. 277:1999;F966-F973
6. Arima S., Kohagura K., Takeuchi K., et al. Biphasic vasodilator action of troglitazone on the renal microcirculation. J Am Soc Nephrol. 13:2002;342-349
7. Isshiki K., Haneda M., Koya D., et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes. 49:2000;1022-1032
8. McCarthy K.J., Routh R.E., et al. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int. 58:2000;2341-2350
9. Bank N., Aynedjian H.S. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int. 43:1993;1306-1312
10. Forstermann U., Schmidt H.H., Pollock J.S., et al. Isoforms of nitric oxide synthase Characterization and purification from different cell types. Biochem Pharmacol. 42:1991;1849-1857
11. Komers R., Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol. 284:2003;F1121-F1137
12. Wilcox C.S., Welch W.J., Murad F., et al. Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc Natl Acad Sci USA. 89:1992;11993-11997
13. Mohaupt M.G., Elzie J.L., Ahn K.Y., et al. Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. Kidney Int. 46:1994;653-665
14. Bachmann S., Bosse H.M., Mundel P. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am J Physiol. 268:1995;F885-F898
15. Veelken R., Hilgers K.F., Hartner A., et al. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol. 11:2000;71-79
16. Taketomi S., Ikeda H., Ishikawa E., et al. Determination of overall insulin sensitivity in diabetic mice, KK. Horm Metab Res. 14:1982;14-18
17. Matsuo T., Shino A. Induction of diabetic alterations by goldthioglucose-obesity in KK, ICR and C57BL mice. Diabetologia. 8:1972;391-397
18. Ikeda H. KK mouse. Diabetes Res Clin Pract. 24:(suppl):1994;S313-S316
19. Wehner H., Hohn D., Faix-Scheade U., et al. Glomerular changes in mice with spontaneous hereditary diabetes. Lab Invest. 27:1972;331-340
20. Duhault J., Lebon F., Boulanger M. KK mice as a model of microangiopathic lesions in diabetes. Bibl Anat. 11:1973;453-458
21. Okazaki M., Saito Y., Udaka Y., et al. Diabetic nephropathy in KK and KK-Ay mice. Exp Anim. 51:2002;191-196
22. Shike T., Hirose S., Kobayashi M., et al. Susceptibility and negative epistatic loci contributing to type 2 diabetes and related phenotypes in a KK/Ta mouse model. Diabetes. 50:2001;1943-1948
23. Nishimoto Y., Tomida T., Matsui H., et al. Decrease in renal medullary endothelial nitric oxide synthase of fructose-fed, salt-sensitive hypertensive rats. Hypertension. 40:2002;190-194
24. Aizawa-Abe M., Ogawa Y., Masuzaki H., et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 105:2000;1243-1252
25. Weibel E.R. Stereological Methods. Practical Methods for Biological Morphometry. vol 1:1979;40-116 Academic Press, London, UK
26. Hishiki T., Shirato I., Takahashi Y., et al. Podocyte injury predicts prognosis in patients with IgA nephropathy using a small amount of renal biopsy tissue. Kidney Blood Press Res. 24:2001;99-104
27. Koya D., Lee I.K., Ishii H., et al. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol. 8:1997;426-435
28. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38. BMJ. 317:1998;703-713
29. Kemnitz J.W., Elson D.F., Roecker E.B., et al. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes. 43:1994;204-211
30. Lee M.K., Miles P.D., Khoursheed M., et al. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 43:1994;1435-1439
31. Ma L.J., Marcantoni C., Linton M.F., et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 59:2001;1899-1910
32. Mogensen C.E., Christensen C.K., Vittinghus E. The stages in diabetic renal disease With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 32:(suppl 2):1983;64-78
33. Komers R., Lindsley J.N., Oyama T.T., et al. Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes. Am J Physiol Renal Physiol. 279:2000;F573-F583
34. Stockand J.D., Sansom S.C. Regulation of filtration rate by glomerular mesangial cells in health and diabetic renal disease. Am J Kidney Dis. 29:1997;971-981
35. Choi K.C., Kim N.H., An M.R., et al. Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney Int. 60:(suppl):1997;S23-S27
36. Ishii N., Patel K.P., Lane P.H., et al. Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol. 12:2001;1630-1639
37. Schwartz D., Schwartz I.F., Blantz R.C. An analysis of renal nitric oxide contribution to hyperfiltration in diabetic rats. J Lab Clin Med. 137:2001;107-114
38. Thomson S.C., Vallon V., Blantz R.C. Kidney function in early diabetes The tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol. 286:2004;F8-F15
39. Calnek D.S., Mazzella L., Roser S., et al. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 23:2003;52-57
40. Feliers D., Duraisamy S., Faulkner J.L., et al. Activation of renal signaling pathways in db/db mice with type 2 diabetes. Kidney Int. 60:2001;495-504
41. Dimmeler S., Fleming I., Fisslthaler B., et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 399:1999;601-605
42. Zeng G., Nystrom F.H., Ravichandran L.V., et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 101:2000;1539-1545